Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
CMOC to Acquire Equinox Gold’s Brazilian Mines in $1 Billion Deal to Expand Precious Metals Portfolio 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
CRANBURY, N.J., Sept. 13, 2016 -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of therapies for rare and orphan diseases, today announced that Chip Baird, Chief Financial Officer, will present a corporate overview at the Bank of America Merrill Lynch Global Healthcare Conference 2016 on September 14, 2016 in London, UK at 9:45am UTC (5:45am ET).
An audio webcast of the presentation can be accessed through the Investors section of the Amicus Therapeutics corporate website at http://ir.amicusrx.com/events.cfm, and will be archived for 90 days.
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq:FOLD) is a global biotechnology company at the forefront of therapies for rare and orphan diseases. The Company has a robust pipeline of advanced therapies for a broad range of human genetic diseases. Amicus’ lead programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease, SD-101 for Epidermolysis Bullosa (EB), as well as novel enzyme replacement therapy (ERT) and biologic products for Fabry disease, Pompe disease, and other rare and devastating diseases.
FOLD–G
CONTACTS: Investors/Media: Amicus Therapeutics Sara Pellegrino Senior Director, Investor Relations [email protected] (609) 662-5044 Media: MWW PR Sean Conley [email protected] (646) 381-9096
